Pharma-Bio Serv, Inc.

Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026

Pharma-Bio Serv reported Q3 revenue of approximately $2.3 million, up roughly $0.4 million versus the same period last year, with nine-month revenue of about $7.3 million, up approximately $0.5 million year over year. The company posted a narrow Q3 net loss of $14 thousand, an improvement of about $190 thousand from the prior year, while nine-month net income reached approximately $252 thousand, up roughly $352 thousand year over year. CEO Victor Sanchez attributed the improved performance to client relationships, sharper focus on markets where the firm's regulatory and compliance expertise creates competitive advantage, and continued operating efficiencies, and said he expects momentum to carry through the final quarter of the fiscal year.

•1mo ago

Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2026

Pharma-Bio Serv reported revenue of approximately $2.7 million for the quarter ended April 30, 2026, an increase of $0.3 million compared to the prior year. Net income for the quarter was approximately $0.2 million, up $0.1 million year-over-year, while six-month revenue reached $5.0 million with net income of $0.3 million. Management attributed the improved financial performance to a strategic focus on high-return markets and disciplined cost management.

•4mo ago